In the past week, MOR stock has gone up by 0.31%, with a monthly decline of -0.58% and a quarterly surge of 56.55%. The volatility ratio for the week is 0.64%, and the volatility levels for the last 30 days are 0.64% for Morphosys AG ADR. The simple moving average for the past 20 days is -0.15% for MOR’s stock, with a 67.93% simple moving average for the past 200 days.
Is It Worth Investing in Morphosys AG ADR (NASDAQ: MOR) Right Now?
The 36-month beta value for MOR is also noteworthy at 1.14. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MOR is 150.21M, and at present, short sellers hold a 1.02% of that float. The average trading volume of MOR on April 26, 2024 was 1.84M shares.
MOR) stock’s latest price update
Morphosys AG ADR (NASDAQ: MOR)’s stock price has gone decline by -0.52 in comparison to its previous close of 18.13, however, the company has experienced a 0.31% increase in its stock price over the last five trading days. Accesswire reported 2024-04-24 that Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis will be highlighted during an oral presentation on Friday, May 31, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The congress is being held in Chicago, Illinois, from May 31 to June 4, 2024.
Analysts’ Opinion of MOR
Morgan Stanley, on the other hand, stated in their research note that they expect to see MOR reach a price target of $10.40, previously predicting the price at $9.20. The rating they have provided for MOR stocks is “Equal-Weight” according to the report published on January 16th, 2024.
Morgan Stanley gave a rating of “Overweight” to MOR, setting the target price at $9.20 in the report published on October 13th of the previous year.
MOR Trading at 0.62% from the 50-Day Moving Average
After a stumble in the market that brought MOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.48% of loss for the given period.
Volatility was left at 0.64%, however, over the last 30 days, the volatility rate increased by 0.64%, as shares sank -0.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.59% upper at present.
During the last 5 trading sessions, MOR rose by +0.42%, which changed the moving average for the period of 200-days by +136.94% in comparison to the 20-day moving average, which settled at $18.06. In addition, Morphosys AG ADR saw 82.17% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for MOR
Current profitability levels for the company are sitting at:
- -1.06 for the present operating margin
- 0.76 for the gross margin
The net margin for Morphosys AG ADR stands at -0.79. The total capital return value is set at -0.14. Equity return is now at value -185.77, with -8.61 for asset returns.
Based on Morphosys AG ADR (MOR), the company’s capital structure generated 0.93 points at debt to capital in total, while cash flow to debt ratio is standing at -0.45. The debt to equity ratio resting at 12.97. The interest coverage ratio of the stock is -1.91.
Currently, EBITDA for the company is -97.74 million with net debt to EBITDA at -6.1. When we switch over and look at the enterprise to sales, we see a ratio of 12.68. The receivables turnover for the company is 5.59for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.08.
Conclusion
In summary, Morphosys AG ADR (MOR) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
